{
    "clinical_study": {
        "@rank": "122804", 
        "acronym": "MI_ICSI", 
        "arm_group": [
            {
                "arm_group_label": "untreated", 
                "arm_group_type": "Active Comparator", 
                "description": "Semen was prepared with routinely used media"
            }, 
            {
                "arm_group_label": "myo-inositol", 
                "arm_group_type": "Experimental", 
                "description": "routinely used semen preparation media have been enriched with myo-inositol 2mg/ml.\nin particular the stock solution was prepared in order to add 15microliters per ml of medium"
            }
        ], 
        "brief_summary": {
            "textblock": "In the present trial, the investigators aim to evaluate whether semen myo-inositol (MI)\n      treatment is able to improve IVF outcomes.\n\n      In particular, retrieved oocytes will be randomly divided in two groups, one group will be\n      inseminated with MI treated semen while the other will be inseminated with untreated semen."
        }, 
        "brief_title": "Effect of Myoinositol Treatment of Spermatozoa on in Vitro Fertilization Outcome: a Prospective, Randomized Sibling-oocyte Study", 
        "condition": "Couple Sterility", 
        "condition_browse": {
            "mesh_term": "Infertility"
        }, 
        "detailed_description": {
            "textblock": "Myo is synthesized from glucose-6-phosphate, it is a precursor of second messengers in the\n      cell signaling pathways and it is involved in the regulation of intracellular calcium.\n\n      Literature data have demonstrated the MI play a crucial role in reproduction, indeed, oocyte\n      and spematozoa are nursed in a medium congaing hig MI concentration.\n\n      Furthermore, it has been demonstrated that, in oligoasthenoteratozoospermic patients, in\n      vitro incubation with 2 mg/ml of myo increase significantly the number of spermatozoa with\n      high mitochondrial  membrane potential (MMP). Moreover, it has been found that the in vitro\n      fertilization rate is correlated with the percentage of high MMP spermatozoa."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  couple counselled for IVF\n\n        Exclusion Criteria:\n\n          -  cryopreserved sample"
            }, 
            "gender": "Male", 
            "maximum_age": "42 Years", 
            "minimum_age": "30 Years"
        }, 
        "firstreceived_date": "January 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02050672", 
            "org_study_id": "MI_ICSI"
        }, 
        "intervention": [
            {
                "arm_group_label": "myo-inositol", 
                "intervention_name": "Myo-inositol", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "untreated", 
                "intervention_name": "untreated", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Inositol"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Myoinositol", 
            "ART", 
            "EMBRYO QUALITY"
        ], 
        "lastchanged_date": "January 29, 2014", 
        "location": {
            "contact": {
                "last_name": "Patrizia Rubino, PhD", 
                "phone": "0270103344"
            }, 
            "facility": {
                "address": {
                    "city": "Milan", 
                    "country": "Italy"
                }, 
                "name": "TECNOLAB"
            }, 
            "investigator": {
                "last_name": "Patrizia Rubino, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Myoinositol Treatment of Spermatozoa on in Vitro Fertilization Outcome: a Prospective, Randomized Sibling-oocyte Study", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: National Institute of Health"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Fetilization rate", 
            "time_frame": "Day 1"
        }, 
        "reference": [
            {
                "PMID": "22656408", 
                "citation": "Condorelli RA, La Vignera S, Bellanca S, Vicari E, Calogero AE. Myoinositol: does it improve sperm mitochondrial function and sperm motility? Urology. 2012 Jun;79(6):1290-5. doi: 10.1016/j.urology.2012.03.005."
            }, 
            {
                "PMID": "22086556", 
                "citation": "Nomikos M, Swann K, Lai FA. Starting a new life: sperm PLC-zeta mobilizes the Ca2+ signal that induces egg activation and embryo development: an essential phospholipase C with implications for male infertility. Bioessays. 2012 Feb;34(2):126-34. doi: 10.1002/bies.201100127. Epub 2011 Nov 16. Review."
            }, 
            {
                "PMID": "21434479", 
                "citation": "Condorelli RA, La Vignera S, Di Bari F, Unfer V, Calogero AE. Effects of myoinositol on sperm mitochondrial function in-vitro. Eur Rev Med Pharmacol Sci. 2011 Feb;15(2):129-34."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02050672"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Embryo quality", 
            "time_frame": "Day 2 to Day 5"
        }, 
        "source": "AGUNCO Obstetrics and Gynecology Centre", 
        "sponsors": {
            "collaborator": {
                "agency": "TECNOLAB center for assisted reproductive technologies", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "AGUNCO Obstetrics and Gynecology Centre", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}